CAMBRIDGE, Massachusetts, April 3, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced that 21 new U.S. non-profit organizations have received grants as part of the company’s $19.5 million commitment to its FY2022 Corporate Social Responsibility program. Combined with its initial investment of $20 million in FY2021, Takeda is delivering a collective amount of $39.5 million to help improve equity among under-resourced communities in the areas of health, education, the environment and providing access to healthy foods.
“When we launched our U.S. Corporate Social Responsibility program in FY2021, our aim was to help communities address these four specific areas of social disparities that affect a person’s overall health. Our goal was to plant a seed to help enable long-term, sustainable and meaningful change,” said Julie Kim, president of Takeda’s U.S. Business Unit and U.S. Country Head. “As we evolve our program, we will continue listening to our communities and partners so we can help them make meaningful change locally, while also looking for ways to scale and widen the impact.”
Takeda’s U.S. Corporate Social Responsibility grant applications are reviewed on a rolling basis from the beginning of its fiscal year (April) through the end (March). Takeda partners with local and regional organizations that align with its philanthropic focus areas and share its values and commitment to improving people’s lives for the better.
The work of these 21 organizations will help expand community support in the communities of Greater Boston, San Diego, Atlanta, Chicago, Minneapolis and Los Angeles.
Promoting Food System Equity for vulnerable families in communities around the country:
Promoting Health Equity to create social, physical and economic environments that promote health equity for all:
Supporting Healthier Environments to enhance climate resiliency initiatives:
Promoting Greater Educational Equity to help advance K-8 math programs to promote greater educational equity:
Highlights and progress on the company’s U.S. Corporate Social Responsibility program is further detailed in the company’s recently debuted Takeda Cares for Communities Report, a comprehensive look at the initiatives and partnerships that are making a difference in the lives of communities across the country.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
U.S. and International Media
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.